The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Official Title: Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Study ID: NCT01804140
Brief Summary: This is a screening study to detect BRAF V600 mutation-positive patients for enrollment into clinical research studies of Zelboraf (vemurafenib). Tumor samples will be collected and analyzed from eligible patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma. All institutions with identified patients as defined by this screening protocol will have potential access to the separate vemurafenib protocol MO28072.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Sedona, Arizona, United States
, Tucson, Arizona, United States
, Burbank, California, United States
, Rancho Cucamonga, California, United States
, Denver, Colorado, United States
, Ocala, Florida, United States
, Woodbury, Minnesota, United States
, Columbia, Missouri, United States
, Las Vegas, Nevada, United States
, Nashville, Tennessee, United States
, Amarillo, Texas, United States
, Austin, Texas, United States
, Dallas, Texas, United States
, Dallas, Texas, United States
, Dallas, Texas, United States
, Denton, Texas, United States
, McAllen, Texas, United States
, Tyler, Texas, United States
, Spokane, Washington, United States
, Yakima, Washington, United States
Name: Clinical Trials
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR